Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effects of Sitagliptin on Gastric Emptying in Healthy Subjects
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Royal Adelaide Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT00501657
- Locations
- 🇦🇺
Discipline of Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia
A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)
- Conditions
- Interventions
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 555
- Registration Number
- NCT00481663
A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT00477581
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Effect of Januvia on Beta Cell Function in Patients With Diabetes Mellitus
- Conditions
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2009-09-23
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00425490
- Locations
- 🇮🇱
Sheba_Medical_Center, Tel Hashomer, Israel
Beta-Cell Function and Sitagliptin Trial (BEST)
- Conditions
- Interventions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2012-01-02
- Target Recruit Count
- 21
- Registration Number
- NCT00420511
- Locations
- 🇨🇦
Leadership Sinai Centre for Diabetes, Toronto, Ontario, Canada
Incretins in Impaired Fasting Glucose
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 22
- Registration Number
- NCT00364377
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)
- Conditions
- Interventions
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 262
- Registration Number
- NCT00350779
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 91
- Registration Number
- NCT00095056
Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)
- Conditions
- Interventions
- First Posted Date
- 2004-07-13
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 741
- Registration Number
- NCT00087516
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.